Maternal Smoking Exposure and Newborn Outcomes: Study Using Urinary Cotinine

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

126 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-10-13

Study Completion Date

2026-03-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prenatal exposure to tobacco smoke-whether from active maternal smoking or secondhand exposure-has been linked to adverse neonatal adaptation and metabolic stress. This single-center prospective observational cohort will quantify maternal smoking exposure using maternal urinary cotinine around delivery and examine its association with early neonatal physiologic and biochemical outcomes within the first 24 hours of life.

Participants will be pregnant individuals delivering at a tertiary academic hospital and their newborns. After consent, mothers will provide a urine sample for cotinine measurement. Based on pre-specified cotinine thresholds and maternal history, dyads will be classified into three exposure groups: Active smoker, Passive exposure, or No exposure. No experimental intervention is administered; all neonatal assessments are part of routine peripartum care.

Neonatal data collected (per standard practice) will include: umbilical cord blood gas parameters (pH, base excess, lactate) and fetal carboxyhemoglobin (FCOHb); birthweight; vital signs/blood pressure at \~6 hours; routine laboratory indices (e.g., hemogram, lipids such as HDL/LDL where available per unit protocol); heel-prick TSH from the standard newborn screen; and hearing screening result prior to discharge. Additional maternal and perinatal covariates (e.g., age, parity, gestational age, delivery mode, intrapartum events) will be recorded to support adjusted analyses. No extra phlebotomy beyond standard care will be performed; the study leverages existing clinical samples and measurements.

Primary objective is to determine whether higher maternal cotinine-defined exposure is associated with greater metabolic stress at birth (indexed by cord lactate and related gas parameters) and higher FCOHb. Key secondary objectives include evaluating associations with birthweight, early blood pressure, TSH, hearing screen outcomes, and routine laboratory markers. Prespecified subgroup and sensitivity analyses (e.g., by gestational age strata or delivery mode) will be conducted as feasible.

The planned sample includes approximately three cotinine-stratified cohorts recruited consecutively. Statistical analyses will follow a pre-registered plan using multivariable regression to adjust for confounders; ROC analyses may be used to explore cotinine thresholds predictive of adverse neonatal indices. Enrollment is anticipated to start October 13, 2025, with primary data collection completed within 2-3 months of recruitment initiation.

This study will provide pragmatic, prospectively collected evidence on how biochemically verified maternal tobacco exposure relates to immediate neonatal metabolic, cardiovascular, endocrine, and auditory outcomes, using measurements obtainable in routine care.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Monoamine Oxidases in Smoking Pregnant Women and Newborns

NCT00169390

Smoking Pregnancy Newborn

COMPLETED

Pregnant Women's Knowledge of the Active and Passive Smoking Effects on Pregnancy and the Fetus

NCT06117943

Pregnant Women's Tabacco Exposure

UNKNOWN

Examining a New Biomarker of Nicotine Use Among Pregnant Women Who Participated in the New England SCRIPT

NCT00519766

Smoking Tobacco Use Disorder

COMPLETED

Maternal Smoking During Pregnancy and Female Fetal Testosterone Levels

NCT02610751

Smoking

COMPLETED

Metabolism of Nicotine and Cotinine in Pregnant African-American Women

NCT00341640

Pregnancy Smokers

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tobacco Smoke Pollution Maternal Exposure During Pregnancy Infant, Newborn Carbon Monoxide Poisoning

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Maternal Active Smoking (Cotinine-Defined)

Mother reports active cigarette smoking during pregnancy and urinary cotinine consistent with active smoking per laboratory cutoffs. Newborn outcomes (cord blood gas incl. pH/base excess/lactate, FCOHb), birthweight, 6-hour blood pressure/vitals, heel-prick TSH, hearing screen, and routine labs are recorded within 24 hours of birth. No experimental intervention is administered.

No interventions assigned to this group

Maternal Passive Tobacco Exposure (Secondhand; Cotinine-Defined)

Mother denies active smoking but reports secondhand exposure; urinary cotinine detectable yet below active-smoker threshold per laboratory cutoffs. Same neonatal measurements and timing as other cohorts; no experimental intervention.

No interventions assigned to this group

No Tobacco Exposure (Reference)

Mother denies smoking and secondhand exposure; urinary cotinine negative/undetectable per laboratory cutoffs. Same neonatal measurements collected within routine care; no experimental intervention.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Liveborn neonate delivered at the study hospital, aged 0-72 hours at assessment.
* Routine umbilical cord blood gas available at birth (pH, base excess, lactate).
* Maternal urinary cotinine available around delivery (to classify exposure: active, passive, none).
* Parent/guardian provides informed consent for use of neonatal data obtained from routine care.
* Standard newborn assessments obtainable within 72 hours (e.g., birthweight, \~6-hour vitals/BP, TSH at 24-48 h, hearing screen ≤72 h per unit practice).

Exclusion Criteria

* Emergent clinical scenarios where any research step could delay urgent care.
* Major congenital anomaly/condition that precludes standard assessments (e.g., cord gas not feasible) per clinician judgment.
* No maternal urine available for cotinine measurement (exposure cannot be defined).
* Prior enrollment of the same neonate (no re-enrollment).

Minimum Eligible Age

0 Minutes

Maximum Eligible Age

72 Hours

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes